Beijing, China

Jingshu Xie

USPTO Granted Patents = 10 

Average Co-Inventor Count = 9.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
10 patents (USPTO):

Title: Jingshu Xie: Innovator in Cancer Treatment

Introduction

Jingshu Xie is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative cancer treatments. With a total of 10 patents to his name, Xie's work focuses on advancing therapeutic options for patients suffering from cancer.

Latest Patents

Among his latest patents are groundbreaking discoveries related to anti-PD-1 antibodies and anti-CD40 antibodies. The anti-PD-1 antibodies are designed to target the Programmed Cell Death Protein 1, offering new methods for treating cancer. Additionally, his work on anti-CD40 antibodies provides further advancements in cancer therapy, showcasing the potential of these antigen-binding fragments in clinical applications.

Career Highlights

Jingshu Xie has worked with notable companies in the biopharmaceutical sector, including Eucure Biopharma Co., Ltd. and Biocytogen Pharmaceuticals Co., Ltd. His experience in these organizations has allowed him to contribute to the development of innovative treatments that address critical health challenges.

Collaborations

Xie has collaborated with esteemed colleagues in his field, including Chen Wang and Chunyan Dong. These partnerships have fostered a collaborative environment that enhances the research and development of effective cancer therapies.

Conclusion

Jingshu Xie's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the biopharmaceutical industry. His work continues to pave the way for advancements in cancer therapies, ultimately benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…